AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12463653 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation at one week after operation
Number of subjects: 39
Study 12463653 — intervention group
Group type: COMPARATOR
Intervention: Late mobilisation at four weeks after operation
Number of subjects: 39
Study 9729561 — intervention group
Group type: EXPERIMENTAL
Intervention: Caf capsule (4.45 mg/kg body wt)
Number of subjects: 9
Study 9729561 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated Cof
Number of subjects: 9
Study 9729561 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated Cof with Caf added
Number of subjects: 9
Study 9729561 — intervention group
Group type: COMPARATOR
Intervention: Regular Cof
Number of subjects: 9
Study 9729561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7640591 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care patients
Number of subjects: 2356
Study 7640591 — intervention group
Group type: COMPARATOR
Intervention: Accident and emergency patients
Number of subjects: 2356
Study 2534084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 24
Study 2534084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 24
Study 2534084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction of refined carbohydrate
Number of subjects: 24
Study 2534084 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 comparable controls)
Number of subjects: 24
Study 4846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 45
Study 4846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (Dexedrine)
Number of subjects: 45
Study 4846329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 4846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant drugs (Dexedrine)
Number of subjects: 45
Study 4846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressant drugs (Phenobarbitone)
Number of subjects: 45
Study 4846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally stimulant and depressant drugs
Number of subjects: 45
Study 31829664 — intervention group
Group type: EXPERIMENTAL
Intervention: Live counseling
Number of subjects: 251
Study 31829664 — intervention group
Group type: COMPARATOR
Intervention: Automated content
Number of subjects: 251
Study 30689494 — intervention group
Group type: EXPERIMENTAL
Intervention: CHICOS (tailored intervention)
Number of subjects: 1294
Study 30689494 — intervention group
Group type: EXPERIMENTAL
Intervention: Untailored intervention (iPad-based Vaccine Information Sheet)
Number of subjects: 1294
Study 30689494 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1294
Study 29072001 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-acupuncture therapy
Number of subjects: 60
Study 29072001 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 26165955 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 109
Study 26165955 — intervention group
Group type: COMPARATOR
Intervention: No Continuous Passive Motion (no CPM)
Number of subjects: 109
Study 23186338 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD patients
Number of subjects: 20
Study 22000080 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping condition
Number of subjects: 0
Study 22000080 — intervention group
Group type: COMPARATOR
Intervention: Non-overlapping condition
Number of subjects: 0
Study 18438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up therapy (sulfasalazine monotherapy, then methotrexate added after 3 months, then hydroxychloroquine added at maximum tolerated dosage)
Number of subjects: 96
Study 18438851 — intervention group
Group type: COMPARATOR
Intervention: Parallel triple therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Number of subjects: 96
Study 18438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up therapy
Number of subjects: 96
Study 18438851 — intervention group
Group type: COMPARATOR
Intervention: Parallel triple therapy
Number of subjects: 96
Study 18438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up therapy and Parallel triple therapy
Number of subjects: 96
Study 16557155 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:2 compression-to-ventilation ratio
Number of subjects: 20
Study 16557155 — intervention group
Group type: COMPARATOR
Intervention: 15:2 compression-to-ventilation ratio
Number of subjects: 20
Study 16557155 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:2 compression-to-ventilation ratio with ITD
Number of subjects: 20
Study 16279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric prediction methods using Kaplan-Meier estimator
Number of subjects: 0
Study 16279273 — intervention group
Group type: COMPARATOR
Intervention: Parametric prediction model for failure-time outcomes
Number of subjects: 0
Study 11504315 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance after orchiectomy
Number of subjects: 104
Study 11504315 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 104
Study 9217034 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (psychotherapy)
Number of subjects: 86
Study 9217034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 86
Study 9217034 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and hormone therapy
Number of subjects: 86
Study 7700061 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 3302112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg bd)
Number of subjects: 20
Study 3302112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30076996 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (learning to deceive)
Number of subjects: 42
Study 30076996 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no learning to deceive)
Number of subjects: 42
Study 27149769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) applied semi-annually
Number of subjects: 1018
Study 27149769 — intervention group
Group type: COMPARATOR
Intervention: Fluoride mouth rinse (FMR) once per week
Number of subjects: 1018
Study 25618752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined add-on supplementation of omega-3 fatty acids, vitamin E, vitamin A, copper, and selenium
Number of subjects: 100
Study 25618752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 100
Study 22972879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) administered for 10 days (4 days before to 5 days after surgery)
Number of subjects: 33
Study 22972879 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 10 days (4 days before to 5 days after surgery)
Number of subjects: 33
Study 20601414 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (20 ml oral solution)
Number of subjects: 234
Study 20601414 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g intravenous)
Number of subjects: 234
Study 18211575 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical wound treatments
Number of subjects: 547
Study 18211575 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor healing progress by early criteria at 4 weeks
Number of subjects: 547
Study 18211575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcers and venous leg ulcers subgroups
Number of subjects: 547
Study 16580189 — intervention group
Group type: EXPERIMENTAL
Intervention: Single office spirometry
Number of subjects: 1206
Study 16580189 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention strategy (control group)
Number of subjects: 1206
Study 14563183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (i.v. 25 mg/week for 3 months, then oral 25 mg/week for 3 months)
Number of subjects: 54
Study 14563183 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (oral 2 mg/kg per day for 6 months)
Number of subjects: 54
Study 14563183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 54
Study 14563183 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 54
Study 10908771 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 14
Study 8720610 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg acipimox
Number of subjects: 10
Study 8720610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1546351 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol
Number of subjects: 39
Study 1546351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 0
Study 3986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 30 mg
Number of subjects: 0
Study 3986070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac
Number of subjects: 0
Study 3986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 0
Study 28920142 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 60
Study 28920142 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 27118616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided arthrocentesis
Number of subjects: 20
Study 27118616 — intervention group
Group type: COMPARATOR
Intervention: Conventional arthrocentesis
Number of subjects: 20
Study 25340399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry participants in the Iowa Gambling Task
Number of subjects: 0
Study 25340399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry participants in the delay discounting task
Number of subjects: 0
Study 25340399 — intervention group
Group type: COMPARATOR
Intervention: Sated participants or participants with smaller appetite in the Iowa Gambling Task
Number of subjects: 0
Study 22474203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography plus ultrasound
Number of subjects: 2809
Study 22474203 — intervention group
Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 2809
Study 22474203 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental incidence-screening ultrasound
Number of subjects: 2809
Study 22474203 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after mammography and ultrasound
Number of subjects: 2809
Study 22474203 — intervention group
Group type: COMPARATOR
Intervention: Mammography and ultrasound
Number of subjects: 2809
Study 22474203 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2809
Study 22474203 — intervention group
Group type: COMPARATOR
Intervention: Supplemental ultrasound
Number of subjects: 2809
Study 22474203 — intervention group
Group type: COMPARATOR
Intervention: MRI after negative mammography and ultrasound results
Number of subjects: 2809
Study 20823729 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 379
Study 20823729 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment sessions targeting interoceptive and situational exposure exercises
Number of subjects: 379
Study 18516070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry
Number of subjects: 12
Study 18516070 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 12
Study 18516070 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study 15963091 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus efavirenz
Number of subjects: 69
Study 15963091 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors
Number of subjects: 69
Study 12373695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (daily dose titrated to 2400 mg or maximum tolerated dose)
Number of subjects: 19
Study 12373695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12373695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 19
Study 10676475 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc concentration analysis
Number of subjects: 1155
Study 10676475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair zinc concentration analysis
Number of subjects: 1155
Study 10676475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall zinc status assessment
Number of subjects: 1155
Study 7586360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systemic heparin dose (ACT > 250 seconds; n = 17)
Number of subjects: 52
Study 7586360 — intervention group
Group type: EXPERIMENTAL
Intervention: Full heparin dose (ACT > 480 seconds; n = 18)
Number of subjects: 52
Study 7586360 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncoated circuits with full heparin dose; n = 17)
Number of subjects: 52
Study 2346795 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST/LOW-YIELD
Number of subjects: 7
Study 2346795 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST/HIGH-YIELD
Number of subjects: 7
Study 2346795 — intervention group
Group type: COMPARATOR
Intervention: FED/LOW-YIELD
Number of subjects: 7
Study 2346795 — intervention group
Group type: COMPARATOR
Intervention: FED/HIGH-YIELD
Number of subjects: 7
Study 2346795 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 7
Study 2346795 — intervention group
Group type: COMPARATOR
Intervention: FED
Number of subjects: 7
Study 2346795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory session
Number of subjects: 7
Study 508494 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan
Number of subjects: 24
Study 508494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 24
Study 31809970 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 °C saline impregnated tampon and hot saline irrigation
Number of subjects: 130
Study 31809970 — intervention group
Group type: COMPARATOR
Intervention: 22 °C saline impregnated tampon and saline irrigation
Number of subjects: 130
Study 29985652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovoil™
Number of subjects: 101
Study 29985652 — intervention group
Group type: COMPARATOR
Intervention: LiteOil®
Number of subjects: 101
Study 29985652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oils
Number of subjects: 101
Study 28676733 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical Block (PB)
Number of subjects: 84
Study 28676733 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Sedation (IVS)
Number of subjects: 84
Study 28676733 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 84
Study 26423784 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg (initially 20 mg was considered but reduced due to bleeding events)
Number of subjects: 99
Study 26423784 — intervention group
Group type: COMPARATOR
Intervention: Urokinase 100,000 UI every 24 h for a maximum of 6 days
Number of subjects: 99
Study 23708690 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein formula (HP)
Number of subjects: 351
Study 23708690 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein formula (LP)
Number of subjects: 351
Study 20800241 — intervention group
Group type: EXPERIMENTAL
Intervention: Open group (cardiotomy suction and open venous reservoir)
Number of subjects: 75
Study 20800241 — intervention group
Group type: COMPARATOR
Intervention: Nonsuction group (open venous reservoir without cardiotomy suction)
Number of subjects: 75
Study 20800241 — intervention group
Group type: COMPARATOR
Intervention: Closed group (without cardiotomy suction and open venous reservoir)
Number of subjects: 75
Study 20800241 — intervention group
Group type: EXPERIMENTAL
Intervention: Open group
Number of subjects: 75
Study 20800241 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 19122549 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa
Number of subjects: 24
Study 19122549 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional vaporizer)
Number of subjects: 24
Study 17969886 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipe for nourishing Gan-Shen
Number of subjects: 121
Study 17969886 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard PD treatment)
Number of subjects: 121
Study 11014981 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis psychoeducation
Number of subjects: 47
Study 11014981 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control)
Number of subjects: 47
Study 8994317 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE-vaccine (0.4 microgram)
Number of subjects: 522
Study 8994317 — intervention group
Group type: EXPERIMENTAL
Intervention: TBE-vaccine (0.75 microgram)
Number of subjects: 522
Study 8994317 — intervention group
Group type: COMPARATOR
Intervention: TBE-vaccine (1.5 micrograms)
Number of subjects: 522
Study 1479106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/gm) twice daily for 4 weeks
Number of subjects: 0
Study 1479106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0
Study 6365838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 78
Study 6365838 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study 30117230 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical training
Number of subjects: 110
Study 30117230 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 110
Study 29905824 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.8 g milk protein/d
Number of subjects: 0
Study 29905824 — intervention group
Group type: COMPARATOR
Intervention: 4.4 g milk protein/d
Number of subjects: 0
Study 29905824 — intervention group
Group type: COMPARATOR
Intervention: 4.4 g milk protein + 4.4 g rice protein/d
Number of subjects: 0
Study 29905824 — intervention group
Group type: COMPARATOR
Intervention: Non-nitrogenous placebo
Number of subjects: 0
Study 26889605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl B12 (75 μg/kg)
Number of subjects: 57
Study 26889605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 57
Study 26889605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl B12
Number of subjects: 57
Study 24890528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetyl-salicylic acid (ASA)
Number of subjects: 10000
Study 24890528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose clonidine
Number of subjects: 10000
Study 24890528 — intervention group
Group type: COMPARATOR
Intervention: Placebo for acetyl-salicylic acid
Number of subjects: 10000
Study 24890528 — intervention group
Group type: COMPARATOR
Intervention: Placebo for clonidine
Number of subjects: 10000
Study 23106885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60
Study 23106885 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 60
Study 20148772 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy-guided sevoflurane administration
Number of subjects: 78
Study 20148772 — intervention group
Group type: COMPARATOR
Intervention: Standard practice sevoflurane administration
Number of subjects: 78
Study 19402358 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT-based treatment
Number of subjects: 700
Study 16306545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulation model applied to baseline WESDR population with type 2 diabetes
Number of subjects: 0
Study 12355675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medications
Number of subjects: 0
Study 12355675 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pharmacologic interventions
Number of subjects: 0
Study 12355675 — intervention group
Group type: COMPARATOR
Intervention: Standard psychotherapies
Number of subjects: 0
Study 10514397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen patch
Number of subjects: 36
Study 10514397 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study 7661588 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination (PE) of the breast conducted by female health workers
Number of subjects: 0
Study 7661588 — intervention group
Group type: COMPARATOR
Intervention: Breast self-examination (BSE)
Number of subjects: 0
Study 7661588 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 0
Study 1742002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin
Number of subjects: 101
Study 1742002 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression
Number of subjects: 101
Study 1742002 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical muscle stimulation
Number of subjects: 101
Study 1742002 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 30280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stressful life events and negative parent-child interaction assessed at ages 2-5
Number of subjects: 364
Study 30280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of inhibitory control
Number of subjects: 364
Study 30280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Late childhood problem behavior
Number of subjects: 364
Study 30280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental drug use
Number of subjects: 364
Study 30227941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 30227941 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 26387692 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol (2 mg per kg body weight given in a single infusion over 2 h, repeated every 4 months)
Number of subjects: 18
Study 26387692 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (1 mg per kg body weight over 4 h on 3 successive days, repeated every 4 months)
Number of subjects: 18